

Application Note





INTRODUCTION

Gene Therapy (GT) is a way to treat disease at the genetic level. If a gene or nucleotide can be identified that is responsible for a disease, the theory exists that replacing the gene will cure the disorder.

GT has been proposed to treat many diseases including, but not limited to, congenital blindness, hemophilia, Parkinson's and Multiple Myeloma.

To date, several GT products have been approved and are commercially available around the world.





Microfluidizer[®] Technology in Cell Lysing for Gene Therapy

HOW GENE THERAPY IS USED

There are several ways GT can be used: a mutated gene can be replaced, a mutated and dysfunctional gene can be knocked out, or a new gene can be introduced to help the body fight off the disease.


To deliver those therapeutic genes, the most commonly used carriers are viral vectors. This is due to several advantages associated with their properties. Viruses can infect cells efficiently, be able to target a wide range of host cells and achieve high levels of Some viral vectors can even transfection. transduce non-dividing cells and are also nonpathogenic. Four of the main classes of viral vectors used in preclinical and clinical applications are adenoviruses, adeno-associated viruses (AAVs), retroviruses, and lentiviruses. Adenoviruses and AAVs are sometimes preferred over the other two classes since they do not integrate themselves into the genome.

WHEN CELL LYSING IS REQUIRED

Virus production involves multiple upstream production processes and downstream purification steps.

Developing and optimizing scalable viral vector production, harvest and purification processes is critical and can be challenging. Virus preparation methods for bench top scale usually include procedures that are difficult to scaleup, time and labor consuming and present residual contamination issues.

Vectors such as AAVs are commonly grown in mammalian cells (HEK) cells or insect cells and therefore, cell rupture is required to release and harvest those vectors. The conventional method for lysing cells within the manufacturing environment has been multiple rounds of freeze-thaw cycles. However, the potential contamination issues associated with the freeze-thaw process make it less than ideal way for large scale production. Furthermore, the process is both time and labor intensive.



MICROFLUIDIZER TECHNOLOGY

The Microfluidizer[®] technology is an ideal alternative cell lysing method for harvesting vectors. The unique design (Figure 1) ensures fluid pressure is converted to highly controlled shear forces more efficiently and consistently than generally achievable on other technologies.

The key to the Microfluidizer[®] processor's remarkable efficiency is the design of our exclusive fixed-geometry Interaction Chamber[™]. As cells are forced through the Interaction Chamber[™] under constant pressure and controlled temperatures, the exact right amount of shear force is applied uniformly to rupture the cell membranes without damaging the viruses. Plus, the Microfluidizer[®] technology is seamlessly scalable from lab to production and a range of cGMP ready processors are available.





Microfluidizer® Technology in Cell Lysing for Gene Therapy

A CASE STUDY

A case study is presented here to compare the virus recovery efficiency between freeze-thaw method and the Microfluidizer® technology.

In this study, AAV vectors were grown inside HEK293 cells and resuspended in Tris buffer before lysing using both methods. In the freezethaw method there were 5 repeated cycles of freezing cell suspension in dry ice/isopropanol bath and then thawing it at 37°C in order to rupture the cells.

Using Microfluidizer[®] technology homogenization method, cell suspension was processed once through the Microfluidizer[®] processor equipped with a H30Z (200 μ m) interaction chamber at 4,000psi (275 bars).

In both cases, the lysate was centrifuged for 30 minutes to remove debris before being analyzed by droplet digital polymerase chain reaction (ddPCR) to quantify AAV titers. Microscopic images of cells before and after the Microfluidizer homogenization step are shown in Figure 2 – which clearly indicates that one pass was able to rupture almost all the cells.




Figure 2: Microscopic images of cells before and after the Microfluidizer® technology homogenization step

Figure 3 shows that under such high efficiency, the amount of AAV harvested using the Microfluidizer® technology is significantly, about 50%, higher than that obtained through the freeze-thaw method.

Furthermore, the freeze-thaw method took 5 hours to complete while the entire process was done in less than an hour including all preparation and sanitizing steps on the Microfluidizer[®] processor.




Figure 3: Amount of AAV recovered after cell lysing with freeze-thaw method & Microfluidizer® technology



Microfluidics[™]

Microfluidizer® Technology in Cell Lysing for Gene Therapy

BENEFITS OF MICROFLUIDIZER TECHNOLOGY

In summary, Microfluidizer[®] technology provides a number of benefits in viral vector production:

High yield – Effectively ruptures cells to release viruses without damaging vectors. Processing through Microfluidizer® processors can also potentially avoid problems with virus agglomeration and binding to membranes, which drastically reduces vector yield, thereby achieving higher yields compare to other methods.

Scalability – Scale up from lab to production linearly with guaranteed results.

cGMP – Biopharmaceutical models are engineered with full cGMP compliance.

Easier for downstream processes – Break cells gently yet efficiently, resulting in large cell wall fragments which are easier to separate from the much smaller viral vectors. The process can also be set to shear the cellular DNA and reduce viscosity. Both make the downstream clarification and filtration processes much easier.

No chemical/enzyme contamination – achieve media-free, negligible-wear processing. No need for chemical lysis method, which means no extra detergent removal step and simplified downstream processes.

No costly chemicals – Do not need or can significantly reduce the amount of costly nuclease such as Benzonase.





©2019 Microfluidics Int'l Corp